Literature DB >> 11810519

Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens.

K. V. I. Rolston1, G. P. Bodey, A. W. Chow.   

Abstract

Entities:  

Year:  1999        PMID： 11810519     DOI： 10.1007/s101560050037

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


× No keyword cloud information.
  3 in total

1.  Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.

Authors:  Konstantinos Z Vardakas; Michael N Mavros; Nikolaos Roussos; Matthew E Falagas
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

Review 2.  Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.

Authors:  Shuli Svetitsky; Leonard Leibovici; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

3.  Immobilised teicoplanin does not demonstrate antimicrobial activity against Staphylococcus aureus.

Authors:  S Britton; K Lee; L Azizova; G Shaw; W Nishio Ayre; J P Mansell
Journal:  Sci Rep       Date:  2022-10-05       Impact factor: 4.996
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.